glecirasib

AXP000030.1 · Targeted small molecule

Platform
small molecule
Targets
KRAS
Originator
Jacobio Pharmaceuticals
Sponsor
Jacobio Pharmaceuticals; Shanghai Allist Pharmaceuticals (Greater China)

Names

NameTypeSource
glecirasibpreferred name, INNcurator, ncit
艾瑞凯brandpress
JAB-21822codencit

Cross-references

NCI Thesaurus
C181904
Wikidata
Q138303900
FDA UNII
UP75WH4QKM

Approvals

No regulatory approval recorded.

Clinical trials (17)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07827261A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 22026-092028-1236Non-small Cell Lung Cancer
NCT07601048A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard TreatmentNot yet recruitingPhase 32026-062028-05450KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
NCT07670013SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II StudyRecruitingPhase 22026-04-012028-0143NSCLC
NCT07339839Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLCNot yet recruitingPhase 1/22026-03-012027-09-3042KRAS G12C; NSCLC Stage IV
NCT07164170A Phase 2 Clinical Study of Combination Therapy With ABSK043 and GlecirasibRecruitingPhase 22025-09-222028-12-3086Non-Small Cell Lung Cancer
NCT06838338JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRCActive not recruitingPhase 12025-03-202026-0330Colorectal Cancer
NCT06563999Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 22024-11-012027-11-01120Lung Cancer Stage III; Mutation
NCT06416410JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationRecruitingPhase 32024-08-072029-09-30392Advanced Non-squamous Non-small-cell Lung Cancer; Metastatic Non-squamous Non Small Cell Lung Cancer
NCT06162169A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy SubjectsCompletedPhase 12023-11-252024-02-2066Healthy Subjects
NCT06008288A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.RecruitingPhase 22023-10-272026-12-3188KRAS P.G12C; Pancreatic Cancer; Solid Tumor
NCT05920941Mass Balance Study of [14C]JAB-21822CompletedPhase 12023-07-082023-08-096Mass Balance Study in Healthy Subjects
NCT05875493A Food Effect Study of JAB-21822 in Healthy SubjectsCompletedPhase 12023-05-122023-06-1418Food Effect in Healthy Participants
NCT05276726A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1RecruitingPhase 1/22022-08-172027-08104Non-small Cell Lung Cancer
NCT05288205Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationRecruitingPhase 1/22022-04-142027-03240Colorectal Cancer; KRAS P.G12C; Non-small Cell Lung Cancer; Pancreatic Ductal Carcinoma
NCT05194995JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C MutationActive not recruitingPhase 1/22022-02-172025-04-3048Advanced Colorectal Cancer; Appendiceal Cancer; Small Intestinal Cancer
NCT05002270JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C MutationCompletedPhase 1/22021-09-032025-02-1229Advanced Solid Tumor; CRC; NSCLC
NCT05009329A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in ChinaActive not recruitingPhase 1/22021-07-262026-08315NSCLC; Solid Tumor

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41325755Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial.The Lancet. Respiratory medicine2026cited by trial NCT05288205
PMID 41344351Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials.The lancet. Gastroenterology & hepatology2026cited by trial NCT05009329
PMID 42384131The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation.Human cell2026cited by trial NCT05009329
PMID 39762419Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial.Nature medicine2025cited by trial NCT05009329
PMID 40333694JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies.Clinical cancer research : an official journal of the American Association for Cancer Research2025cited by trial NCT05288205
PMID 41037823Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.Cancer communications (London, England)2025cited by trial NCT05002270

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41994634Non-small cell lung cancer research: advances and persistent challenges.Frontiers in oncology2026name in abstract: glecirasib
PMID 42511798KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.International journal of molecular sciences2026name in abstract: glecirasib
PMID 42551924[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].Gan to kagaku ryoho. Cancer & chemotherapy2026name in abstract: glecirasib
PMID 42587211Correction: The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation.Human cell2026name in title: glecirasib
PMID 42622884KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Medical oncology (Northwood, London, England)2026name in abstract: glecirasib
PMID 42846599Glecirasib treatment in KRAS G12C-positive non-small cell lung cancer with leptomeningeal metastasis.Frontiers in oncology2026name in title: glecirasib
PMID 43001251From "undruggable" to tractable: Therapeutic advances targeting Kristen rat sarcoma viral homolog glycine to cysteine mutation at codon 12 (KRAS G12C)-mutant cancers and emerging resistance mechanisms.Cancer pathogenesis and therapy2026name in abstract: glecirasib
PMID 39825361KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors.Journal of translational medicine2025name in abstract: JAB-21822
PMID 39875337Design, Structure Optimization, and Preclinical Characterization of JAB-21822, a Covalent Inhibitor of KRASG12C.Journal of medicinal chemistry2025name in title: JAB-21822
PMID 40024323Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future.European journal of pharmacology2025name in abstract: glecirasib
PMID 40304209Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312.Cancer research communications2025name in title: glecirasib
PMID 41158041[Advances in Diagnosis and Targeted Therapy of KRASG12C Mutant Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer2025name in abstract: glecirasib

Notes

KRAS G12C. Approved China (NMPA, May 2025) as 艾瑞凯; China rights licensed to Allist 2024. Wikidata QID not confirmed.

How to cite

glecirasib (AXP000030.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000030.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.